Principal, National Sector Leader for HCLS, KPMG US
Healthcare Life Sciences
Taking steps toward adopting computer software assurance (CSA) in life sciences
Disruption caused by chimeric antigen receptor T-cell (CAR T) therapy, a type of cell and gene therapy, to exploring standard business models in the life sciences industry.
KPMG reports on the state of life sciences industry digital transformation, automation, artificial intelligence, and machine learning
An examination of potential implications for how drug manufacturers manage their portfolios in the wake of the Inflation Reduction Act
A reckoning in the aftermath of COVID
At a recent WSJ Future of Health forum, Ash Shehata, National Healthcare and Life Sciences lead spoke about Deglobalization.
A triple threat across the Americas
IRA will significantly impact prescription costs and insurance coverage for millions of Americans
Deal strategies will focus on risk mitigation, accelerated development, or risk sharing (licensing, partnerships, R&D collaborations).
Smaller Deals, More Partnerships, and Continued Innovation in 2022.
KPMG perspective on this innovative technology
With success in clinical trials for a range of mental disorders, psychedelics may soon move to the medical mainstream.
Why the growth of 503Bs may be an opportunity for traditional pharma
Unwinding federal COVID-19 policies will have significant industry impacts.
Reforms to FDA Accelerated Approval Program could include new confirmatory study requirements.
KPMG spearheaded a cross-institutional team of pharma supply-chain leaders to develop a proprietary cybersecurity framework.
Our 2022 Healthcare and Life Sciences Investment Outlook offers a look into industry innovations with the greatest investor interest.
Improving distributor monitoring and compliance in an increasingly complex global life sciences market.
Experience in cell & gene therapies.
How to spot leaders vs. laggards.
An Artificial Intelligence (AI) enabled digital twin is a state-of-the-art simulation of a complex real-world system, enhancing predictive AI.
Life sciences companies have turned a corner in the wake of COVID-19 and are now looking toward a smarter, faster future.
How Chief Accounting Officers can lean into the challenge to enhance their strategic roles.
A near-term niche?
Life sciences companies face unique governance, risks and compliance challenges when implementing SAP S/4HANA technology.
It takes a delicate balance of control and freedom to pursue innovation.
Competition for innovation will continue to drive deal making.
The American Rescue Plan Act of 2021 expands healthcare coverage and provides pandemic funding.
Provides insights on how the political and regulatory environment, and market factors may impact investment decisions.
On November 20, 2020, the Centers for Medicare and Medicaid Services announced the Most Favored Nation Drug Pricing Model.
By 2030, generics manufacturers will need to shift from the status quo and explore one of three avenues for change.
HHS, Department of Labor, and Treasury finalized price transparency requirements for health plans set to take effect beginning in 2022.
FDA finalized a rule and guidance allowing states to submit prescription drug importation proposals and manufacturers to re-label drugs for importation.
An Executive Order directs HHS rulemaking for “most favored nations” pricing for Medicare Part B and D drugs.
Four Executive Orders (EO) described as action to deliver lower prescription drug prices to American Patients.
Failing to resume clinical trials could present as many risks to certain patients as COVID-19.
An opportunity for medical device companies to shape their future customer base.
The Life Sciences Industry is moving towards a dramatically different future based on a number of market drivers.
Private labs seeking to restructure or build to deploy COVID-19 testing operations can benefit from KPMG’s rapid start-up approach.
For businesses making decisions about when and how to reopen their businesses, here is a practical guide to key considerations.
Implications for Healthcare providers.
CMS just announced alternative Part D options that lower seniors’ cost-sharing for insulin, according to the attached issue brief.
Economic support and stimulus bill.
Analysis of the 2020 KPMG Healthcare and Life Sciences Investment Outlook survey sheds light on how the investment landscape will be impacted by influential disruptors, evolving market trends, and policy/regulatory developments.
Despite progress, companies are still facing many questions.
Forward-thinking Life Sciences CXOs will transform Quality from a cost center to a value creator.
Instead of viewing calls for transparency as a burden, pharmaceutical companies can take steps to turn pricing reform to their advantage.
Proposed safe harbor changes open for comment.
Rising to the data challenge.
Reinvent innovation and become an R&D front-runner by 2030.
2019 Health Care & Life Sciences Investment Outlook.
Unlocking value for life sciences organizations.
This CIO Survey is the largest IT leadership study in the world, and summarizes what we learned about the transformational CIO.
KPMG/RAPS survey illustrates the ground medical device companies still have to cover.
Identifying opportunities for life sciences manufacturers.
2018 Program benchmark report.
Innovation in the life sciences finance function.
As new entrants and cross-sector models abound, which direction should healthcare organizations turn?
Blockchain could be a key to interoperability and privacy.
New standard. New challenges.
Healthcare and life sciences will face continued disruption in 2018 as new technologies, economic pressures and consumer/patient demands change the industry.
Register to receive timely insights
Meet our team